Edition:
United States

Ritter Pharmaceuticals Inc (RTTR.OQ)

RTTR.OQ on NASDAQ Stock Exchange Capital Market

0.30USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
196,427
52-wk High
$3.75
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals
Tuesday, 3 Oct 2017 01:34pm EDT 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc :‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing.  Full Article

RITTER PHARMA RAISES $23 MLN TO FUND PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE
Tuesday, 3 Oct 2017 12:00pm EDT 

Oct 3 (Reuters) - Ritter Pharmaceuticals Inc ::RITTER PHARMACEUTICALS, INC. RAISES $23 MILLION TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM IN LACTOSE INTOLERANCE.PROCEEDS WILL ALLOW CO TO FUND INITIATION OF ITS PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE.‍PHASE 3 CLINICAL PROGRAM OF RP-G28 FOR TREATMENT OF LACTOSE INTOLERANCE EXPECTED TO BEGIN IN FIRST HALF OF 2018​.  Full Article

Ritter Pharmaceuticals Inc prices $23,000,000 public offering
Friday, 29 Sep 2017 08:00am EDT 

Sept 29 (Reuters) - Ritter Pharmaceuticals Inc :Ritter Pharmaceuticals, Inc. prices $23,000,000 public offering.Ritter Pharmaceuticals Inc - offering is expected to close on October 3, 2017.  Full Article

Ritter Pharma announces Phase 3 plans after end of Phase 2 meeting with FDA on RP-G28
Friday, 18 Aug 2017 09:30am EDT 

Aug 18 (Reuters) - Ritter Pharmaceuticals Inc ::Ritter Pharmaceuticals announces Phase 3 plans after its end of Phase 2 meeting with FDA on RP-G28 for lactose intolerance.Has incorporated guidance from FDA on key elements of its phase 3 program to support a new drug application (NDA) for RP-G28.Company anticipates initiating phase 3 program during first half of 2018​.  Full Article

Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms
Thursday, 3 Aug 2017 09:30am EDT 

Aug 3 (Reuters) - Ritter Pharmaceuticals Inc :Ritter Pharmaceuticals reports further analysis from its phase 2b/3 trial results demonstrating significant reductions in lactose intolerance symptoms.Ritter Pharmaceuticals - ‍Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments​.Ritter Pharmaceuticals- ‍treatment effect suggests clinically meaningful benefit to subjects in significantly reducing symptoms of lactose intolerance​.Ritter Pharmaceuticals Inc - Study demonstrated safety with no serious adverse events related to treatment.Ritter Pharmaceuticals Inc- ‍Company has been granted an end of phase 2 meeting with FDA, which will take place by end of 2017​.Ritter Pharmaceuticals Inc - Company has also commenced manufacturing efforts and plans to commence phase 3 clinical program in first half of 2018.Ritter Pharmaceuticals- ‍In preparation for phase 3 program, also commenced manufacturing efforts, plans to commence phase 3 clinical program in 1H 2018​.  Full Article

Ritter pharmaceuticals files for offering of up to $10 mln ‍​
Monday, 3 Jul 2017 05:34pm EDT 

July 3 (Reuters) - Ritter Pharmaceuticals Inc ::Ritter Pharmaceuticals files for offering of up to $10 million of class a units consisting of stock and warrants and class b units consisting of preferred stock & warrants ‍​.  Full Article

Ritter Pharmaceuticals enters into a common stock purchase agreement
Tuesday, 9 May 2017 07:34am EDT 

May 9 (Reuters) - Ritter Pharmaceuticals Inc : :Ritter pharmaceuticals says on may 4, entered into a common stock purchase agreement with Aspire Capital Fund.Ritter pharmaceuticals - agreement provides co ability to access up to $6.5 million through sale of shares of co's common stock.Ritter Pharmaceuticals - in consideration for entering into agreement, co agreed to issue to Aspire Capital 137,324 shares of co's common stock.  Full Article

Ritter Pharmaceuticals reports Q1 loss per share $0.14
Tuesday, 9 May 2017 07:26am EDT 

May 9 (Reuters) - Ritter Pharmaceuticals Inc : :Ritter Pharmaceuticals reports first quarter 2017 financial results and provides business updates.Q1 loss per share $0.14.Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Ritter Pharmaceuticals Inc - as of March 31, 2017, Ritter Pharmaceuticals had cash and cash equivalents of approximately $5.1 million.  Full Article

Ritter Pharmaceuticals announces issuance of new patents for its lactose intolerance treatment, RP-G28
Tuesday, 2 May 2017 12:45pm EDT 

May 2 (Reuters) - Ritter Pharmaceuticals Inc : :Ritter Pharmaceuticals announces issuance of new patents for its lactose intolerance treatment, RP-G28, and provides an update on its path forward into Phase 3.Will be holding an end of Phase 2 meeting with FDA to present and discuss Phase 3 plan for RP-G28.  Full Article

Ritter Pharmaceuticals says end of phase 2 meeting with FDA and initiates phase 3 program development activities
Wednesday, 12 Apr 2017 10:00am EDT 

Ritter Pharmaceuticals Inc : Ritter pharmaceuticals, inc. Announces end of phase 2 meeting with the fda and initiates phase 3 program development activities . Ritter pharmaceuticals inc - completed phase 2b/3 trial demonstrated several positive topline results and full analysis of data is underway . Ritter pharmaceuticals -plans to discuss results of its recently completed phase 2b/3 trial and phase 3 plans in preparation of a nda submission of rp-g28 . Ritter pharmaceuticals - no serious adverse events related to rp-g28 were reported in study, further supporting safety profile previously shown in phase 2a study . Ritter pharmaceuticals inc- commenced manufacturing efforts and currently anticipates initiation of phase 3 in first half of 2018 for rp-g28 .Ritter pharma- fda has agreed to schedule an end of phase 2 meeting with company which is expected to take place in q3 of 2017 relating to rp-g28.  Full Article

BRIEF-‍sabby Management reports 9.94 pct passive stakee in Ritter Pharmaceuticals

* ‍sabby Management, LLC​ reports 9.94 percent passive stakee in Ritter Pharmaceuticals Inc as of September 29 - sec filing Source text : http://bit.ly/2yWkm3T Further company coverage: